CTLA4 and melanoma: Recently, Lannone et al. reported that combination treatment with both APCP and anti-CTLA-4 mAb displayed significant retard of tumor growth compared with APCP or anti-CTLA-4 mAb treatment alone in mouse melanoma models [74].